HER-2 positive breast cancer: Decreasing proportion but stable incidence in Finnish population from 1982 to 2005

Breast Cancer Research

Volumn 11, Issue 3, 2009, Pages

  Köninki, Katri ^a   Tanner, Minna ^a,b   Auvinen, Anssi ^c   Isola, Jorma ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; FEMALE; FINLAND; HORMONAL THERAPY; HUMAN; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MAMMOGRAPHY; MENOPAUSE; POISSON DISTRIBUTION; POPULATION; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; COHORT ANALYSIS; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INCIDENCE; METABOLISM; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FINLAND; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 74049120919     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2322     Document Type: Article

References (31)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
2. Demonty G, Bernard-Marty C, Puglisi F, Mancini I, Piccart M. Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer 2007, 43:497-509. 10.1016/j.ejca.2006.10.020, 17223541.
3. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684. 10.1056/NEJMoa052122, 16236738.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, . Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672. 10.1056/NEJMoa052306, 16236737, Herceptin Adjuvant (HERA) Trial Study Team.
5. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, Chan A, Smylie M, Liu M, Falkson C, Pinter T, Fornander T, Shiftan T, Valero V, von Minckwitz G, Mackey J, Tabah-Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram M, Press M, Crown J. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients [abstract]. Breast Cancer Res Treat 2006, 100(Suppl 1):52.
6. Cardoso F, Durbecq V, Sotiriou C, Ross JS. HER-2/neu gene and protein in breast cancer. Molecular oncology of breast cancer 2005, 232-255. Boston: Jones and Bartlett, Ross J, Hortobagyi G.
7. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007, 356:1670-1674. 10.1056/NEJMsr070105, 17442911.
8. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int J Cancer 2006, 119:2417-2422. 10.1002/ijc.22160, 16964611.
9. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991, 49:650-655. 10.1002/ijc.2910490504, 1682277.
10. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992, 10:1044-1048.
11. Finnish Cancer Registry: Cancer statistics. , http://www.cancerregistry.fi/eng/statistics/
12. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994, 33:365-369. 10.3109/02841869409098430, 8018367.
13. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004, 10:4793-4798. 10.1158/1078-0432.CCR-0428-03, 15269154.
14. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, . FinHer Study Investigators Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820. 10.1056/NEJMoa053028, 16495393, FinHer Study Investigators.
15. Glass AG, Hoover RN. Rising incidence of breast cancer: relationship to stage and receptor status. J Natl Cancer Inst 1990, 82:693-696. 10.1093/jnci/82.8.693, 2319611.
16. Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 1994, 74:1523-1524. 10.1002/1097-0142(19940901)74:5<1601::AID-CNCR2820740517>3.0.CO;2-#, 8062185.
17. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003, 21:28-34. 10.1200/JCO.2003.03.088, 12506166.
18. Zhao H, Langerod A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Kåresen R, Botstein D, Børresen-Dale AL, Jeffrey SS. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 2004, 15:2523-2536. 420079, 15034139, 10.1091/mbc.E03-11-0786.
19. Cocquyt V, Van Belle S. Lobular carcinoma in situ and invasive lobular cancer of the breast. Curr Opin Obstet Gynecol 2005, 17:55-60.
20. Hoff ER, Tubbs RR, Myles JL, Procop GW. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol 2002, 117:916-921. 10.1309/4NTU-N6K4-F8JF-EWRX, 12047143.
21. Bane AL, Tjan S, Parkes RK, Andrulis I, O'Malley FP. Invasive lobular carcinoma: to grade or not to grade. Mod Pathol 2005, 18:621-628. 10.1038/modpathol.3800273, 15605082.
22. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, . Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397, Writing Group for the Women's Health Initiative Investigators.
23. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002, 360:942-944. 10.1016/S0140-6736(02)11032-4, 12354487.
24. Hemminki E, Karttunen T, Hovi SL, Karro H. The drug industry and medical practice - the case of menopausal hormone therapy in Estonia. Soc Sci Med 2004, 58:89-97. 10.1016/S0277-9536(03)00150-3, 14572923.
25. Hemminki E, Kyyrönen P, Pukkala E. Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005. Maturitas 2008, 61:299-304. 10.1016/j.maturitas.2008.09.022, 18996655.
26. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004, 101:1490-1500. 10.1002/cncr.20499, 15378477.
27. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004, 96:218-228.
28. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L. Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer 2001, 92:919-922. 10.1002/ijc.1279, 11351317.
29. Reeves GK, Beral V, Green J, Gathani T, Bull D, . Million Women Study Collaborators Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006, 7:910-918. 10.1016/S1470-2045(06)70911-1, 17081916, Million Women Study Collaborators.
30. Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Bützow R, Holli K, Sailas L, Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H. Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 2008, 14:4103-4110. 10.1158/1078-0432.CCR-07-5003, 18593987.
31. Statistics of mass screening activities. , http://www.cancerregistry.fi/eng/statistics/